Patent intelligence · US
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
Oral dosage form of ticagrelor and preparation method thereof
Patent details — US 11723873
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 15, 2023
- Expiration
- Aug 10, 2043
- Applicant
- Elite Pharmaceutical Solution Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/519, A61K47/10, A61K9/0004
Quick answer
US 11723873 (Oral dosage form of ticagrelor and preparation method thereof) is held by Elite Pharmaceutical Solution Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elite Pharmaceutical Solution Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/519, A61K47/10, A61K9/0004, A61K9/0053, A61K9/2018
More from Elite Pharmaceutical Solution Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 11723873?
US 11723873 (Oral dosage form of ticagrelor and preparation method thereof) is held by Elite Pharmaceutical Solution Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11723873?
Elite Pharmaceutical Solution Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 11723873 expire?
Our index shows an expiration date of Aug 10, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.